Clinical trials: Mucinous Tumor
Pancreatic Mucinous-Cystic Neoplasm
Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
This study will evaluate intracystic NanoPac® (Sterile Nanoparticulate Paclitaxel) administered via endoscopic ultrasound-guided fine needle injection (EUS-FNI) in subjects with mucinous cystic pancreatic neoplasms.
- Trial name
- NCT03188991
- Testing
- NanoPac®
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- NanOlogy, LLC
Solid Organ Cancers
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
The purpose of this study is to evaluate the safety of the investigational product GL-ONC1. GL-ONC1, a vaccinia virus, has been genetically modified for use as a potential anti-cancer drug to destroy cancer cells.
- Trial name
- NCT02714374
- Testing
- GL-ONC1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrew Lowy
Intraductal Papillary Mucinous Neoplasms, Pancreatic Exocrine Insufficiency
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Intraductal Papillary Mucinous Neoplasms (IPMN) are pancreatic cystic neoplasms managed through imaging-based surveillance focused on oncologic risk.
- Trial name
- IPEX (NCT07535125)
- Volunteers
- 600 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Fallopian Tube Cancer, Ovarian Cancer
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- S0009 (NCT00008138)
- Testing
- carboplatin, paclitaxel, debulking surgery
- Volunteers
- 62 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, Low Grade Serous Carcinoma
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
This is a phase II, single arm, multi-centre study to assess the efficacy of pembrolizumab in combination with platinum-based chemotherapy (investigator's choice: carboplatin + gemcitabine or carboplatin + pegylated liposomal…
- Conditions
- Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- PERCEPTION (NCT04575961)
- Testing
- Pembrolizumab
- Where
- 2 sites in Germany
- Volunteers
- 33 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Breast Cancer
Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Placing gold markers in the area where the tumor was removed may help doctors better direct radiation therapy and help reduce the risk of cancer…
- Trial name
- NCT00749437
- Testing
- 3-dimensional conformal accelerated partial breast irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Colorectal Cancer
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01079780
- Testing
- cetuximab, ramucirumab, irinotecan hydrochloride
- Where
- 255 sites in United States
- Volunteers
- 136 people
- Sponsor
- Eastern Cooperative Oncology Group
Pseudomyxoma Peritonei
Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei
The main objective of this study is to combine HIPEC regimens with Flura-seq to detect the effects of different HIPEC regimens (cisplatin vs.
- Trial name
- NCT06839378
- Testing
- intravenously inject with 5-FU (400 mg/m2)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Appendiceal Cancer, Appendiceal Adenocarcinoma
Molecular Profiling for Risk Stratification in Appendiceal Cancer
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort.
- Trial name
- NCT07587268
- Testing
- DNA Methylation Profiling, m6A Epitranscriptomic Profiling
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- City of Hope Medical Center
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer
Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation
This research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation.
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
- Trial name
- NCT02132858
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Fox Chase Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of TLK286 in treating patients who have advanced ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00022347
- Testing
- canfosfamide hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00217529
- Testing
- pegfilgrastim, carboplatin, docetaxel
- Where
- 3 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Rare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei
French National Registry of Rare Peritoneal Surface Malignancies
Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France.
- Conditions
- Rare Peritoneal Surface Malignancies, Pseudomyxoma Peritonei, Peritoneal Mesothelioma, Desmoplastic Small Round Cell Tumor
- Trial name
- RENAPE (NCT02834169)
- Testing
- Non interventional
- Where
- 33 sites in France
- Volunteers
- 2,171 people
- Sponsor
- Hospices Civils de Lyon
Adenocarcinoma, Rectal Diseases
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Extramural venous invasion (EMVI) is the spread of microscopic tumour cells into the veins around the tumour. Rectal cancer treatment has improved greatly over recent years.
- Conditions
- Adenocarcinoma, Rectal Diseases, Colorectal Neoplasms, Adenocarcinoma, Mucinous
- Trial name
- MARVEL (NCT01995942)
- Where
- 19 sites in United Kingdom
- Volunteers
- 246 people
- Sponsor
- Royal Marsden NHS Foundation Trust